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Abstract
Shikonin induced necroptosis in Jurkat cells were identified flow cytometrically by the up-regulation of RIP3 in live cells and 
that a proportion of these cells underwent other forms of regulated cell death (RCD) which included parthanatos (< 10%), 
or cleaved PARP (< 10%) and DNA Damage (> 30%). Live necroptotic cells also possessed functioning mitochondria with 
hyper-polarized mitochondria membrane potential and generated a fivefold increase in cellular reactive oxygen species (ROS) 
which was resistant to inhibition by zVAD and necrostatin-1 (Nec-1). After loss of plasma membrane integrity these dead 
necroptotic cells then showed a higher incidence of parthanatos (> 40%), or cleaved PARP (> 15%) but less DNA Damage 
(< 15%). Inhibition of shikonin induced apoptosis and necroptosis by zVAD and Nec-1 respectively resulted in live necrop-
totic cells with an increased incidence of cleaved PARP and reduced levels of DNA Damage respectively. Dead necroptotic 
cells then showed a reduced incidence of parthanatos and DNA Damage after inhibition by zVAD and Nec-1 respectively. 
A high proportion of these dead necroptotic cells (30%) which lacked plasma membrane integrity also displayed functioning 
hyper-polarized mitochondria with high levels of cellular ROS and thus had the capacity to influence the outcome of RCD 
processes rather than just been the end product of cell death, the necrotic cell. Flow cytometry can thus measure multiple 
forms of RCD and the level of cellular ROS and MMP which highlights the inter-connection between cell death processes 
and that a single cell may simultaneously display multiple forms of RCD.
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Abbreviations
ACD  Accidental cell death
ATP  Adenosine triphosphate
CamK II  Ca2 + /Calmodulin-dependent kinase II
Cleaved PARP  Poly (ADP-ribose) polymerase 1
DDR  DNA damage response
DN  Double negative
DNA DSBs  double strand DNA breaks
Drp1  Dynamin guanosine tri-phosphatase
EAPO  Early apoptosis
γHA2X  Histone A2 family X
LAPO  Late apoptosis
MFI  Median fluorescence intensity
MLKL  Pseudokinase mixed lineage kinase 
domain-like protein
MMP  Mitochondrial membrane potential
MPT  Mitochondrial permeability transition 
pore complex
NAD +   Nicotinamide adenine dinucleotide
Nec-1  Necrostatin-1
PDC  Pyruvate dehydrogenase complex
PGAM5  PGAM Family Member 5, Mitochondrial 
Serine/Threonine Protein Phosphatase
QN  Quadruple negative
RCD  Regulated cell death
RIP1  Receptor-interacting serine/threonine-
protein kinase 1
RIP1 APO  RIP1-dependent apoptosis
RIP3  Receptor-interacting serine/threonine-
protein kinase 3
ROS  Reactive oxygen species
RT  Room temperature
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TNFα  Tumour Necrosis Factor alpha
TRADD  TNF receptor type 1-associated with 
death domain protein





The regulated necrotic cell death process (RCD) necroptosis 
is a caspase independent process which after TNFα bind-
ing to the TNF receptor becomes associated with TRADD 
(TNF receptor type 1-associated with death domain protein) 
and TRAF-2 (TNFR-associated factor 2 forming complex I 
[1–6]). This complex together with the RIP1 protein then 
auto-phosphorylates after inhibition of caspase-8 (active cas-
pase-8 cleaves RIP1), [7] which then acts as the first ROS 
sensor in this form of regulated cell death [2–6, 8]. This 
ultimately leads to the up-regulation and phosphorylation of 
RIP3 forming the so called necrosome and to the recruitment 
and phosphorylation of MLKL (pseudokinase mixed lineage 
kinase domain-like protein) at the plasma membrane leading 
to cell lysis Fig. 1 [5, 6, 9–12]. RIP3 has also been reported 
to move to the inner mitochondrial membrane where it’s 
interaction with PDC, CamK II, Drp1 and PGAM5 leads to 
the enhanced production of ROS by mitochondria Fig. 1 [3, 
13, 14]. ROS generated during necroptosis has been previ-
ously shown to enhance auto-phosphorylation of RIP1 and 
was essential for RIP3 recruitment to the necrosome leading 
to enhanced formation of functional necrosomes, with Reac-
tive Oxygen Species (ROS) acting in a positive feedback 
loop ensuring maintenance of necroptosis (Fig. 1). RIP1 is 
mainly located in the cytoplasm in the form of the necro-
some as part of the necroptosis process, however nuclear 
RIP1 has also been shown to associate in a kinase independ-
ent manner and activate PARP1 inducing PARP1-dependent 
regulated necrosis or parthanatos Fig. 1 [15].
The drug shikonin is a naturally occurring naphthoqui-
none has like TNFα [4, 16] been reported to induce apop-
tosis and necroptosis, as well as generate ROS (Fig. 1 [3, 8, 
17, 18]. Necrostatin-1 (Nec-1) has been reported to inhibit 
necroptosis and also the generation of ROS by mitochondria 
but to a lesser extent in the cytoplasm Fig. 1 [3, 8, 16]. Shi-
konin has also been reported to increase the level of γH2AX 
or DNA Damage (as part of the DNA Damage Response, 
DDR), cleaved PARP and also the hyper-activation of 
Fig. 1  Shikonin induction of 
necroptosis, apoptosis, DNA 
Damage, cleaved PARP and 
parthanatos. (1) Shikonin is 
taken up by the cell which 
causes (2) RIP1 auto-phospho-
rylates which phosphorylates 
RIP3 to form the necrosome 
which can be blocked by Nec-1. 
(3) The necrosome then phos-
phorylates MLKL leading to the 
permeablisation of the plasma 
membrane and cell death by 
necroptosis. (4) Phosphoryl-
ated RIP proteins move to the 
mitochondria leading to raised 
MMP or hyperpolarization of 
mitochondria and excessive pro-
duction of ROS. (5) ROS causes 
DNA Damage leading to phos-
phorylation of histone γH2AX 
which can be blocked by Nec-1. 
(6) PARP is cleaved by active 
caspase-3 which is generated 
during apoptosis (7). Parthana-
tos occurs when phosphorylated 




cleaved PARP which zVAD can down-regulate Fig. 1 [8, 
19]. The action of cleaved PARP is also known to reduce 
levels of NAD + resulting in lower ATP levels which has 
been reported to act as a molecular switch towards pro-
grammed necrosis [15]. RIP1 is not only located in the 
cytoplasm which together with RIP3 forms the necrosome, 
but parthanatos is also found in the nucleus associated with 
activated PARP1 and RIP1 in the development of a part-
hanatos response [19–21]. RIP3 has also been reported to 
regulate levels of mitochondrial ROS in glioma cells which 
in turn increased the incidence of double strand breaks in 
DNA (DNA DSBs) leading to an increase in γH2AX or 
DNA Damage resulting in chromatinolysis and necroptosis 
[8]. Jurkat cells have previously been shown to display no 
change in the high level of DNA Damage in live necroptotic 
cells (reduced in dead cells) after treatment with shikonin 
[18]. Shikonin treatment of Jurkat cells were also reported 
to show increased hyper-activation of PARP by γH2AX and 
cleaved PARP in live populations as well as dead necroptotic 
and oncotic cells  (RIP3−ve/Caspase-3−ve) [15, 16, 18]. Thus 
live necroptotic cells are composed of different sub-popu-
lations of cells undergoing caspase-3 independent cleaved 
PARP, parthanatos, DNA Damage or just RIP3 up-regulated 
necroptosis [15, 16, 18].
Mitochondrial activity during the necroptotic process has 
been misreported by the misuse of mitochondrial functional 
probes without using cell viability probes when performing 
flow cytometry [14, 22]. The non-exclusion of dead cells 
induced by the cytotoxic drug in question leads to a mas-
sive under-reporting of the degree of MMP in the remaining 
live cells. This study investigates this discrepancy by using 
a cell viability probe to show changes in MMP and ROS 
generation in live cells undergoing necroptosis as well as 
oncosis, early, late and RIP1-dependent apoptosis and relates 
this to parthanatos, cleaved PARP expression and the degree 
of DNA Damage during RCD and ACD (Accidental Cell 
Death) processes. Further studies investigating the modula-
tion of such responses to shikonin by blockade of necroptosis 
or apoptosis by Nec-1 or zVAD were also performed. This 
flow cytometric approach in the study of multiple forms of 
RCD and ACD highlights the presence of functional hyper-
polarized mitochondria with high levels of ROS in live and 
apparently dead necroptotic cell populations.
Materials and methods
Induction of necroptosis and apoptosis
Jurkat cells (human acute T cell leukaemia cell line) were 
grown in RPMI 1640 medium with 10% FBS and penicil-
lin/streptomycin (Invitrogen, UK) at 37 °C and 5%  CO2 and 
either left untreated or treated with 0.5 μM Shikonin (Santa 
Cruz, USA) for 24 h. Cells were also pre-treated with the 
pan-caspase blocker zVAD (20 μM, Enzo Life Sciences, 
USA) or the necroptosis blocker necrostatin-1 (60 μM, 
Cambridge Bioscience, UK) for 2 h before and during the 
treatment with 0.5 μM Shikonin for 24 h.
Live cell labelling
After treatment part of the harvested cells (1 × 106) were 
labelled with Violet Live Cell Caspase (2 μl/ml, Becton 
Dickinson, USA) and 500 nM CellROX Green (Invitro-
gen, USA) at 37 °C for 1 h. Then incubated with 50 nM 
MitoTracker Deep Red (Invitrogen, USA) and fixable live 
dead stain Zombie NIR (Near Infra-Red) (BioLegend, UK) 
at 37 °C for 15 min. 100,000 events were analysed on an 
ACEA Bioscience Novocyte 3000 flow cytometer.
Intracellular labelling protocol
The remaining Jurkat cells were labelled with fixable live 
dead stain Zombie NIR for 15 min at RT and washed. Pel-
leted cells were sequentially fixed in Solution A (CalTag, 
UK) then permeabilised with 0.25% Triton X-100 (Sigma, 
UK) for 15 min each at RT. Jurkat cells (2 × 106) were incu-
bated for 20 min at RT with 2 μl of anti-RIP3-PE (clone B-2, 
Cat. No. sc-374639, Santa Cruz, USA), cleaved anti-PARP-
PE-CF594 (clone F21-852, Becton Dickinson, USA), anti- 
γH2AX -PE-Cy7 (clone 2F3, BioLegend, UK) and anti-
active caspase-3-BV650 (clone C92-605, Becton Dickinson, 
USA) for 20 min at RT. Washed cells were resuspended in 
400 μl PBS and analysed on a ACEA Bioscience Novocyte 
3000 flow cytometer and 200,000 events analysed.
Flow cytometry
MitoTracker Deep Red and Zombie NIR were excited by the 
633 nm laser and collected at 660/20 nm and 780/60 nm. 
Caspase Violet and Caspase-3-BV650 were excited by the 
405 nm laser and collected at 450/20 nm and 675/30 nm. 
CellROX Green, RIP3-PE, cleaved PARP-PE-CF594, 
γH2AX -PE-Cy7 were excited by the 488 nm laser and 
collected at 530/20 nm, 572/28, 615/20, 780/60 nm respec-
tively. Single colour controls were employed to determine 
the colour compensation using the pre-set voltages on the 
instrument using Novo Express software (ver 1.2.5, ACEA 
Biosciences, USA).
Gating strategies
Unfixed cells were gated on FSC vs SSC removing the 
small debris near the origin with single cells gated on an 
FSC-A vs FSC-H dot-plot. This was followed by a dot-plot 
of Caspase-Violet vs Zombie NIR with a quadrant placed 
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marking off live cells in the double negative quadrant (lower 
left), early apoptotic cells were Caspase  Violet+ve/Zombie 
 NIR−ve (lower right) and lastly with dead cells labelled with 
Caspase  Violet+ve or −ve/Zombie  NIR+ve (upper quadrants) 
indicating late apoptotic and necrotic/oncotic cells respec-
tively (Fig. 1S). Live, early and late apoptotic and oncotic 
populations were gated for CellROX Green vs MitoTracker 
Deep Red with upper-left quadrant CellROX  Green−ve/
MitoTracker Deep  Red+ve or live cells with mitochondrial 
function but without ROS. The upper right quadrant being 
CellROX  Green+ve/MitoTracker Deep  Red+ve or cells with 
mitochondrial function and ROS, lower right quadrant 
being CellROX  Green+ve/MitoTracker Deep  Red−ve or cells 
without mitochondrial function but with ROS (Fig. 2S). 
MitoTracker Deep Red and CellROX Green signals from shi-
konin treatments were referenced to untreated cells (100%) 
then expressed as percentage fold increase, see Fig. 5.
After Zombie NIR labelling, fixation, permeabilisa-
tion and intracellular labelling with antibodies (listed in 
the "Intracellular labelling protocol" section). Cells were 
then analysed by gating on a dot-plot of Caspase-3-BV650 
vs Zombie NIR with a quadrant placed marking off live 
cells in the double negative quadrant (lower left), with 
Caspase-3-BV650+ve/Zombie  NIR−ve (lower right) indi-
cating early apoptotic (EAPO) cells (Fig. 3S, a). Lastly, 
Caspase-3-BV650+ve or −ve/Zombie  NIR+ve upper quadrants 
indicated late apoptotic (LAPO) and oncotic cells, respec-
tively (Fig. 3S, a). Live (including early apoptotic) and both 
dead cell populations were gated separately and analysed 
in RIP3 vs Caspase-3 dot-plots with  RIP3+ve/Caspase-3−ve 
which indicated live cells or necroptosis when RIP3 Median 
Fluorescence Intensity (MFI) was up-regulated (Fig. 3S, b, 
d).  RIP3−ve/Caspase-3+ve cells indicate those that had under-
gone early (EAPO) or late apoptosis (LAPO, Fig. 3S, b, d). 
Double positive events indicate cells of the RIP1-dependent 
apoptosis phenotype (RIP1APO, Fig. 3S, b, d). Double nega-
tive (DN) cells and all other phenotypes were further ana-
lysed for γH2AX and cleaved PARP expression (Fig. 3S, c, 
e). The following populations were identified: DNA Dam-
age (DDR) phenotype were γH2AX+ve/PARP−ve events, 
γH2AX hyper-activation of cleaved PARP (Hyper-Act) or in 
the absence of caspase-3, parthanatos γH2AX +ve/PARP+ve, 
cleaved PARP (PARP) as γH2AX −ve/PARP+ve and negative 
(QN, γH2AX −ve/PARP−ve) as shown in Fig. 3S, c, e.
Statistics
All experiments (at least n = 3) were expressed either as 
average percent positive ± SD, average Median Fluores-
cence Intensity (MFI) ± SD and percent average Median 
Fluorescence Intensity (MFI) normalised to untreated 
cells ± SD. Data were tested for multivariate normality with 
the Kolmogorov–Smirnov goodness of fit test, followed by 
One Way ANOVA (P < 0.5) and then post ad hoc to test 
for significance (P < 0.5) between treatments with Graph-
Pad PRISM ver. 8.4.0 software Inc., USA. Not considered 
significant P > 0.05 (NS), significance was either P < 0.05*, 
P < 0.01**, P < 0.001***, P < 0.0001**** when treated cells 
were compared to untreated and also between treatments 
when analysing γH2AX and PARP.
Results
Induction of necroptosis and apoptosis
Jurkat cells treated with shikonin showed a significant 
increase in early (68%) and late apoptosis (22%, Fig. 2a, 
b). Shikonin induced necroptosis  (RIP3high+ve/Caspase-3−ve) 
with an up-regulation of RIP3 (37%) and RIP1-depend-
ent apoptosis (29%,  RIP3+ve/Caspase-3+ve) compared 
to untreated live cells (Figs. 3a, c and  4). The dead cells 
showed increased levels of RIP1-dependent apoptosis com-
pared to untreated cells (58%, Fig. 3b, d).
Treated live cells were comprised of those undergoing 
necroptosis (4%,  RIP3high+ve/Caspase-3−ve) or were double 
negative (DN) for RIP3/Caspase-3 (14%) together which 
showed a significant two and four fold increase in MMP and 
ROS respectively compared to untreated live cells (Figs. 2S, 
a, e; 3c and 5a, b). There was also a rise in live cells that 
lacked mitochondrial function but showed no significant 
rise in ROS (13% compared to untreated 2%, Figs. 2S, a, e 
and  5c). Early apoptotic treated cells mainly lacked MMP 
(while untreated did not) but generated > 60% more ROS 
(Figs. 2S, b, f and 5c). The remaining treated early apoptotic 
cells with mitochondrial function (7%) generated more ROS 
(50%) than untreated early apoptotic cells (Figs. 2S, b, f and 
5a, b).
Late apoptotic cells mainly lacked mitochondrial func-
tion, but generated 23% more ROS than untreated cells 
(Figs. 2S, c, g and 5c). However, the small percentage of 
late apoptotic cells (2%) with raised MMP (40%) with a 6.5-
fold increase in ROS (Figs. 2S, c, g and 5a, b). Oncotic cells 
 (Zombie+ve/Caspase  violet−ve) which comprised of dead 
necroptotic and dead oncotic DN cells showed a high degree 
of mitochondrial function (30% compared to untreated cells 
5%) with raised MMP (3.6 fold) and eightfold–ninefold 
more ROS than untreated oncotic cells (Figs. 2S, d, h and 
5a, b). Those oncotic cells without mitochondrial function 
showed no increase in detectable ROS (Figs. 2S, d, 5c).
Live cells showed a small increase in the incidence of 
γH2AX hyper-activation of cleaved PARP or parthanatos 
in live necroptotic, RIP1-dependent apoptosis and also late 
apoptotic cells, with a decrease observed in early apoptotic 
cells (Fig. 6a). The incidence of cleaved PARP was sig-
nificantly increased after shikonin treatment in early, live 
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RIP1-dependent apoptosis and both necroptotic populations; 
with decreases in late apoptosis and dead RIP1-dependent 
apoptosis (Fig. 6b). DNA Damage was correspondingly 
decreased after drug treatment in both necroptotic popula-
tions and live RIP1-dependent apoptosis, with an increase 
observed in late apoptotic cells (Fig. 6c).
zVAD blockade of apoptosis
Blockade of shikonin induced apoptosis by zVAD showed a 
decrease in early apoptosis (16%, Fig. 2c). The incidence of 
live necroptotic cells with raised RIP3 MFI was increased 
(14% compared to 4% treated cells, Figs. 3e and 4). Early/
late and RIP1-dependent apoptosis was reduced compared 
to drug treatment (Figs. 3e, f and 4). Correspondingly there 
was a significant increase in live and dead oncotic DN popu-
lations compared to drug and untreated cells (Fig. 3a–f).
The live cells after zVAD blockade of shikonin comprised 
of 14% necroptotic and 53% DN compared to 4% and 14% 
in treated cells respectively (Fig. 3c, e). These live cells 
showed a doubling of cells without mitochondrial function 
which generated ROS (Figs. 2S, i and 5c). Consequently, the 
incidence of double positive live cells was reduced (56%) 
compared to treated cells (70%) but had the same high level 
of MMP as that induced by shikonin treatment (two fold 
increase) and ROS (fourfold increase, Figs. 2S, i and 5a, 
b). Early and late apoptotic cells after zVAD blockade of 
shikonin showed an abrogation of ROS generated by cells 
with functioning mitochondria with no change in the level 
of ROS in cells without mitochondrial function compared 
to drug treatment (Figs. 2S, b, c, f, g, j, k and 5). The inci-
dence of apparently live oncotic cells after zVAD blockade 
was reduced to untreated levels but with the maintenance 
of the high level of MMP and ROS (Figs. 2S, d, h, l and 5a, 
b). However, the incidence of cells without mitochondrial 
Fig. 2  Cell death and caspase-3 
activation assay. Jurkat cells 
were untreated (a), treated 
with 0.5 μM shikonin for 24 h 
(b), pre-treated with 20 μM 
zVAD for 2 h then with 0.5 μM 
shikonin for 24 h (c), pre-treated 
with 60 μM necrostatin-1 (Nec-
1) for 2 h then with 0.5 μM 
shikonin for 24 h (d). Live 
(DN), early apoptotic (EAPO, 
Zombie  NIR−ve/caspase  3+ve), 
late apoptotic (LAPO, Zombie 
 NIR+ve/caspase  3+ve) and 
oncotic cells (Zombie  NIR+ve/
caspase  3−ve). Average % ± SD 
(n = 3) were analysed for sig-
nificance by One Way ANOVA 
(P < 0.5) and post ad hoc tested 
for significance, NS (P > 0.5, 
not significant), significance 
was P < 0.05*, P < 0.01**, 
P < 0.001***, P < 0.0001****, 
with red arrows indicating 
change compared to untreated 
cells (Color figure online)
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function but generated the same level of ROS was increased 
(15%) compared to drug and untreated cells (< 5%, Figs. 2S, 
d, h, l and 5c).
γH2AX hyper-activation of cleaved PARP or parthana-
tos and cleaved PARP was reduced in most cell populations 
after zVAD blockade of shikonin compared to drug treat-
ment except live necroptotic cells which showed an increase 
in cleaved PARP (Fig. 6a, b). In contrast the DNA Damage 
populations was increased in most cell populations after 
zVAD blockade of shikonin compared to drug treatment 
(Fig. 6c).
Necrostatin‑1 blockade of necroptosis
Nec-1 blockade of shikonin reduced early apoptosis (51%) 
compared to drug treatment (68%, Fig. 2d). Such treatment 
blocked necroptosis as indicated by the abrogation of RIP3 
up-regulation (Figs. 3g and 4). While, late apoptosis was 
reduced, the incidence of the live DN population (45%) was 
increased compared to drug treatment (14%, Fig. 3c, d, g, h).
Fig. 3  RIP3 and caspase-3 activation assay. After gating on live and 
dead cells from a Zombie NIR vs. Caspase-3-BV650 dot-plot cells 
were then analysed on a RIP3-PE vs. Caspase-3-BV650 dot-plot. 
The necroptotic phenotype indicated by  RIP3+ve/high+ve/Caspase-3−ve 
which has up-regulated RIP3 Median Fluorescent Intensity (MFI). 
The apoptotic phenotype was  RIP3−ve/Caspase-3+ve, RIP1-dependent 
apoptosis  (RIP3+ve/Caspase-3+ve) and quadruple negative  (RIP3−ve/
Caspase-3−ve). Live (a) and dead (b) untreated cells, or cells treated 
with 0.5 μM shikonin for 24 h (c, d), pre-treated with 20 μM zVAD 
for 2 h then with 0.5 μM shikonin for 24 h (e, f) or pre-treated with 
60 μM Nec-1 for 2 h then with 0.5 μM shikonin for 24 h (g, h). Aver-
age Median Fluorescent Intensity MFI or average % ± SD (n = 3) were 
analysed for significance by One Way ANOVA (P < 0.5) and post ad 
hoc tested for significance, NS (P > 0.5, not significant), significance 
was P < 0.05*, P < 0.01**, P < 0.001***, P < 0.0001****, with red 
arrows indicating change compared to untreated cells (Color figure 
online)
Fig.4  Analysis of RIP3 expression. Live cells expressing RIP3 
but not caspase-3 were analysed for RIP3 expression for untreated 
cells, then average percentage in RIP3 MFI ± SD were deter-
mined for 0.5  μM shikonin (24  h), 0.5  μM shikonin with 20  μM 
zVAD or 0.5  μM shikonin with 60  μM Nec-1. Average percentage 
of RIP3 MFI ± SD (n = 3), were analysed for significance by One 
Way ANOVA (P < 0.5) and post ad hoc tested for significance, NS 
(P =  > 0.5, not significant), significance was P < 0.05*, P < 0.01**, 
P < 0.001***, P < 0.0001**** compared to untreated cells
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This increased the percentage of live DN cells (45%, 
Fig. 3g) resulted in a reduction in live cells with function-
ing mitochondria (49% compared to 70% by drug treat-
ment) but which still displayed increased MMP and ROS 
by 2 and threefold respectively (Figs. 2S, a, e, m and  5a, 
b). Early apoptotic cells showed no change in the degree 
of ROS generation in cells with or without mitochondrial 
function (Figs. 2S, b, c, n, o and 5). While, late apoptotic 
cells with dysfunctional mitochondria showed no significant 
rise in generated ROS levels above untreated cells, the few 
cells with functional mitochondria showed an abrogation of 
ROS (Fig. 4b, c). Oncotic cells with dysfunctional mitochon-
dria showed no change in ROS after Nec-1 blockade, while 
those with functioning mitochondria were reduced (< 4%) 
and showed an abrogation of the raised MMP (> 40%) but 
had a ten fold increase in ROS compared to untreated cells 
(Figs. 2S, d, p and 5a, b, c).
The incidence of γH2AX hyper-activated cleaved PARP 
expressing cells was reduced after Nec-1 blockade of shi-
konin in only early and live RIP1-dependent apoptotic 
populations compared with drug treatment, with no change 
observed in other populations (Fig. 6a). Cleaved PARP was 
increased by Nec-1 in late apoptotic, live necroptotic and 
dead oncotic DN cells compared to drug treatment, with 
a reduction observed in the early apoptotic population 
(Fig. 6b). In contrast, all cells after Nec-1 blockade showed 
reductions in DNA Damage as opposed to the increase 
observed after zVAD blockade of shikonin (Fig. 6c).
Discussion
The main aim of this flow cytometric based study was to 
show that shikonin induced Jurkat cell necroptosis and apop-
tosis (blocked by zVAD and Nec-1) resulted in measurable 
changes in mitochondrial function, MMP and cellular ROS 
in live, early, late apoptotic and oncotic cell populations. 
Unfortunately, the lack of reliable MitoTracker and CELL-
ROX Green data after fixation and permeabilisation has not 
allowed analysis of MMP and ROS in specific cell death 
populations (e.g. live necroptotic cells undergoing part-
hanatos). The assay also tracked the incidence of shikonin 
(blocked by zVAD or Nec-1) induced necroptosis, caspase-3 
dependent apoptosis, RIP1-dependent apoptosis, DN popu-
lations (live and dead oncotic DN cells) as well as the inci-
dence of parthanatos (or γH2AX hyper-activation of PARP), 
cleaved PARP and DNA Damage in these populations. Other 
studies imply that the necroptosis process is typified by the 
presence of dysfunctional mitochondria and high levels of 
ROS, this was mainly due to the misreporting of MitoTracker 
data due to the lack of a cell viability probe [14, 22]. Cyto-
toxic drugs usually cause a high degree of cell death with 
Fig. 5  Mitochondrial MMP, function and cellular ROS analysis. Jur-
kat cells were loaded with violet caspase, Zombie NIR, MitoTracker 
Deep Red and CellROX Green as described in the Materials and 
Methods section. Live (DN), early apoptotic (EAPO, Zombie  NIR+ve/
caspase  violet+ve), late apoptotic (LAPO, Zombie  NIR+ve/caspase 
 violet+ve) and oncotic (Zombie  NIR+ve/caspase  violet−ve) cells were 
analysed for MMP by MitoTracker Deep Red (a), those MMP + ve 
cells analysed for CellROX Green, ROS (b), those MMP-ve cells ana-
lysed for CellROX Green, ROS (c). Untreated cells, 0.5 μM shikonin, 
blockade of shikonin with zVAD (20  μM) or blockade of shikonin 
with Nec-1 (60  μM) were analysed. Mean percentage of MFI was 
normalised to untreated cells ± SD, (n = 3) were analysed for signifi-
cance by One Way ANOVA (P < 0.5) and post ad hoc tested for sig-
nificance, NS (P > 0.5, not significant), significance was P < 0.05*, 
P < 0.01**, P < 0.001***, P < 0.0001**** compared to untreated 
cells and between treatments as indicated
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the possibility that the remaining live cells (with functioning 
mitochondria) are thus hidden by the dead cell population 
(without functioning mitochondria) leading to a misreport-
ing of the health of mitochondria within the live cell frac-
tion [14]. Necroptosis occurs over a period of time and the 
high level of ROS being detected is due at some point to the 
mitochondria in live necroptotic cells being functional and 
in a hyper-polarized state leading to the generation of most 
of the ROS detected Fig. 1 [2, 14, 21–24]. Other intracel-
lular sources of ROS have been shown to be less affected by 
blockade with Nec-1 (unlike mitochondrial generated ROS) 
indicating that a small but significant proportion of ROS 
is not generated by mitochondria [8]. Although this does 
not indicate an absolute mitochondria requirement in the 
necroptotic process [2, 14, 21–24].
The use of multi-parameter flow cytometry to analyse 
RCD and ACD processes showed that live necroptotic 
cells (indicated by a 37% up-regulation of RIP3 which was 
abrogated by Nec-1) had functioning mitochondria with 
high levels of MMP and ROS which can be divided into 
Fig. 6  γH2AX hyper-activation 
of cleaved PARP or parthanatos, 
cleaved PARP and γH2AX or 
DNA Damage assay. Jurkat 
untreated, treated with 0.5 μM 
shikonin or pre-treated zVAD 
(20 μM) or Necrostatin-1 
(60 μM) for 2 h then incubated 
with 0.5 μM shikonin for 24 h. 
After gating on live and dead 
cells from a Zombie NIR vs. 
Caspase-3-BV650 dot-plot 
untreated or treated live and 
dead Jurkat cells were analysed 
on a RIP3-PE v Caspase-
3-BV650 dot-plot. From 
which early and late apoptotic, 
necroptotic, RIP1-dependent 
apoptotic and double negative 
(DN) populations were analysed 
for γH2AX and cleaved PARP, 
see Figs. 1S and 2S for detailed 
information. The incidence of 
γH2AX hyper-activation of 
cleaved PARP or parthanatos 
(a), cleaved PARP (b) and DNA 
Damage (c) were determined 
for all populations listed above. 
Average % ± SD, (n = 3) were 
analysed for significance by One 
Way ANOVA (P  < 0.5) and post 
ad hoc tested for significance, 
NS (P > 0.5, not significant), 
significance was P < 0.05*, 
P < 0.01**, P < 0.001***, 
P < 0.0001**** compared to 




the basic necroptotic phenotype which were negative for 
both γH2AX and cleaved PARP, while a high proportion of 
the necroptotic population displayed DNA Damage which 
was not increased by the high levels of ROS in these cells 
as may have been expected, see pathway of ROS induction 
of DNA Damage Fig. 1 [8, 14, 19]. The shikonin induced 
necroptosis within the live cell fraction also generated at a 
low incidence two more definable necroptotic populations 
which displayed cleaved PARP and parthanatos respec-
tively, see pathway in Fig. 1 [8, 14, 19]. Early, late and 
RIP1-dependent apoptotic cells had little mitochondrial 
function but such early and live RIP1-dependent apop-
totic cells showed increased ROS compared to untreated 
cells which was abrogated by zVAD. Early apoptotic and 
live RIP1-dependent apoptotic cells showed increased 
cleaved PARP (reduced by zVAD), with DNA Damage 
being reduced by Nec-1 blockade of shikonin (Fig. 1). 
zVAD as expected reduced levels of cleaved PARP and 
γH2AX hyper-activation of PARP in the dead apoptotic 
populations but increased the level of DNA Damage in 
dead RIP1-dependent apoptosis which Nec-1 reduced.
Once mitochondria became dysfunctional the ROS gener-
ated must have fallen relatively rapidly given that ROS levels 
in the live cell population without mitochondrial function 
have similar lower levels of ROS as those cells undergo-
ing RIP1-dependent, early and late apoptosis. It would have 
been interesting to show how the level of ROS generated 
specifically from increasingly hyper-polarized mitochondria 
changed over time during the process of necroptosis and 
ultimately cell death. This time-course approach could also 
be used to monitor the effect Nec-1 blockade has on shikonin 
induced ROS and changes in MMP as it has been shown 
to significantly reduce ROS generated by mitochondria but 
not cellular ROS [8]. When these live necroptotic cells lose 
plasma membrane integrity or undergo cell death, the mito-
chondria in a proportion of these cells along with the live 
DN phenotype become more hyper-polarized (by 70%), pre-
sumably these cells make more ATP by such activity while 
at the same time double the level of ROS generated. Such 
implied increased energy levels indicate that these ‘dead’ 
necroptotic cells could perhaps have the capacity to influ-
ence ongoing biological processes even when the cell has 
lost plasma membrane integrity or has undergone the clas-
sic definition of cell death. It would also be interesting to 
observe how these biologically hyper-active cells initially 
develop, mature and degrade by studying these cells over 
time which may give an insight into their potential to alter 
the outcome of RCD and ACD processes.
More of these dead necroptotic cells have also then 
switched from mainly a DNA Damage phenotype to a part-
hanatos phenotype compared to live necroptotic cells. This 
indicated that the high level of ROS generated by these cells 
resulted in the γH2AX hyper-activation of cleaved PARP 
to generate this parthanatos population of dead necroptotic 
cells, see pathway of ROS driving development of parthana-
tos in Fig. 1. While, dead oncotic DN cells did not undergo 
such a change in RCD phenotypes significantly even though 
these cells also generated high levels of ROS, see Fig. 1.
Inhibitor blockade of shikonin did not change the degree 
of MMP and ROS generation in the live necroptotic cell phe-
notype but did result in increased cleaved PARP with reduc-
tions in DNA Damage by drug and Nec-1 but not zVAD. 
This indicated an enhancement of DNA repair mechanisms 
after Nec-1 blockade of shikonin which resulted in no change 
in the low incidence of necroptotic cells which displayed 
parthanatos, see pathway in Fig. 1. Upon cell death, dead 
necroptotic cells after inhibitor treatment showed no change 
in levels of cleaved PARP compared to drug induced levels, 
but there were reductions in DNA Damage by Nec-1 block-
ade of shikonin this apparently leading to increased levels 
of dead necroptotic cells which displayed parthanatos (com-
pared to live necroptotic cells), this being decreased by zVAD 
but unchanged by Nec-1. In contrast dead oncotic DN cells 
showed no significant change in the incidence of parthana-
tos and DNA Damage after inhibitor treatments, although 
Nec-1 did increase the incidence of cleaved PARP, zVAD 
correspondingly decreased cleaved PARP. This indicated that 
shikonin acted upon a proportion of live cells which resulted 
in a down-regulation of RIP3 (rather than up-regulation to 
induce necroptosis) making them the live DN phenotype, 
they also showed low levels of cleaved PARP and γH2AX but 
high levels of MMP and ROS. This phenotypic profile did not 
change significantly upon cell death even though a high pro-
portion of these cells showed hyper-polarized mitochondria 
with high levels of ROS but did not result in any increase in 
cell death markers. Although inhibition of shikonin reduced 
the incidence of this population, Nec-1 reduced MMP and 
increased the cleaved PARP dead oncotic DN population. 
Why shikonin induced this differential effect upon a cell line 
such as Jurkat T cells is difficult to ascertain but perhaps indi-
cates that cells in a culture respond differently to the drug due 
to perhaps nutrient levels, functionality of organelles such as 
mitochondria, intracellular ROS levels and also the stage of 
cell division. This leads to shikonin apparently inducing more 
apoptosis and less detectable necroptosis with a high propor-
tion of live cells moving to a DN phenotype which showed 
little sign of an RCD process analysed for in this study.
This flow cytometric based study of some of the biologi-
cal functions of cells undergoing necroptosis along with 
the dynamic changes in the incidence of parthanatos and 
DNA Damage in response to shikonin and blockade of both 
necroptosis or apoptosis highlights the interconnectivity of 
numerous RCD processes. Given that necroptotic cells can 
also undergo parthanatos, DNA Damage or neither, perhaps 
these processes should no longer be classed as completely 
separate forms of cell death, as cells appear to move from 
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displaying several specific forms of RCD to others during 
their response to undergoing cell death. The definition of cell 
death may also be required to be reviewed given that lack 
of plasma membrane integrity does not necessarily mean 
that the cell at least initially after loss of plasma membrane 
integrity is not biologically functional given the presence of 
hyper-polarized functional mitochondria.
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